Expanded Access for the Treatment of Cancers With Rearranged During Transfection (RET) Activation

Conditions:   Non Small Cell Lung Cancer;   Medullary Thyroid Cancer;   Colon Cancer;   Breast Cancer;   Pancreatic Cancer;   Papillary Thyroid Cancer;   Other Solid Tumors With Evidence of Activating RET Alteration Intervention:   Drug: LOXO-292 Sponsors:   Loxo Oncology, Inc.;   Eli Lilly and Company Available
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials